Xin Wang1, Nicolas L Palaskas2, Syed Wamique Yusuf2, Jun-Ichi Abe2, Juan Lopez-Mattei2, Jose Banchs2, Gregory W Gladish3, Percy Lee4, Zhongxing Liao4, Anita Deswal2, Steven H Lin5. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, People's Republic of China. 2. Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: shlin@mdanderson.org.
Abstract
INTRODUCTION: Late cardiotoxicity related to radiotherapy (RT) in breast cancer and Hodgkin's lymphoma has been well-reported. However, the relatively higher cardiac dose exposure for esophageal cancer (EC) may result in the earlier onset of cardiac diseases. In this report, we examined the incidence, onset, and long-term survival outcomes of high-grade cardiac events after RT in a large cohort of patients with EC. METHODS: Between March 2005 and August 2017, a total of 479 patients with EC from a prospectively maintained institutional database at The University of Texas MD Anderson Cancer Center were analyzed. All patients were treated with either intensity-modulated RT or proton beam therapy, either preoperatively or definitively. We focused on any grade 3 or higher (G3+) cardiac events according to the Common Terminology Criteria for Adverse Events, version 5.0. RESULTS: G3+ cardiac events occurred in 18% of patients at a median of 7 months with a median follow-up time of 76 months. Preexisting cardiac disease (p = 0.001) and radiation modality (intensity-modulated RT versus proton beam therapy) (p = 0.027) were significantly associated with G3+ cardiac events. Under multivariable analysis, the mean heart dose, particularly of less than 15 Gy, was associated with reduced G3+ events. Furthermore, G3+ cardiac events were associated with worse overall survival (p = 0.041). CONCLUSIONS: Severe cardiac events were relatively common in patients with early onset EC after RT, especially those with preexisting cardiac disease and higher radiation doses to the heart. Optimal treatment approaches should be taken to reduce cumulative doses to the heart, especially for patients with preexisting cardiac disease.
INTRODUCTION: Late cardiotoxicity related to radiotherapy (RT) in breast cancer and Hodgkin's lymphoma has been well-reported. However, the relatively higher cardiac dose exposure for esophageal cancer (EC) may result in the earlier onset of cardiac diseases. In this report, we examined the incidence, onset, and long-term survival outcomes of high-grade cardiac events after RT in a large cohort of patients with EC. METHODS: Between March 2005 and August 2017, a total of 479 patients with EC from a prospectively maintained institutional database at The University of Texas MD Anderson Cancer Center were analyzed. All patients were treated with either intensity-modulated RT or proton beam therapy, either preoperatively or definitively. We focused on any grade 3 or higher (G3+) cardiac events according to the Common Terminology Criteria for Adverse Events, version 5.0. RESULTS: G3+ cardiac events occurred in 18% of patients at a median of 7 months with a median follow-up time of 76 months. Preexisting cardiac disease (p = 0.001) and radiation modality (intensity-modulated RT versus proton beam therapy) (p = 0.027) were significantly associated with G3+ cardiac events. Under multivariable analysis, the mean heart dose, particularly of less than 15 Gy, was associated with reduced G3+ events. Furthermore, G3+ cardiac events were associated with worse overall survival (p = 0.041). CONCLUSIONS: Severe cardiac events were relatively common in patients with early onset EC after RT, especially those with preexisting cardiac disease and higher radiation doses to the heart. Optimal treatment approaches should be taken to reduce cumulative doses to the heart, especially for patients with preexisting cardiac disease.
Authors: M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang Journal: Lancet Date: 2005-12-17 Impact factor: 79.321
Authors: Jeffrey D Bradley; Rebecca Paulus; Ritsuko Komaki; Gregory Masters; George Blumenschein; Steven Schild; Jeffrey Bogart; Chen Hu; Kenneth Forster; Anthony Magliocco; Vivek Kavadi; Yolanda I Garces; Samir Narayan; Puneeth Iyengar; Cliff Robinson; Raymond B Wynn; Christopher Koprowski; Joanne Meng; Jonathan Beitler; Rakesh Gaur; Walter Curran; Hak Choy Journal: Lancet Oncol Date: 2015-01-16 Impact factor: 41.316
Authors: Frederika A van Nimwegen; Michael Schaapveld; Cécile P M Janus; Augustinus D G Krol; Eefke J Petersen; John M M Raemaekers; Wouter E M Kok; Berthe M P Aleman; Flora E van Leeuwen Journal: JAMA Intern Med Date: 2015-06 Impact factor: 21.873
Authors: Anthony J Swerdlow; Craig D Higgins; Paul Smith; David Cunningham; Barry W Hancock; Alan Horwich; Peter J Hoskin; Andrew Lister; John A Radford; Ama Z S Rohatiner; David C Linch Journal: J Natl Cancer Inst Date: 2007-02-07 Impact factor: 13.506
Authors: Berthe M P Aleman; Alexandra W van den Belt-Dusebout; Willem J Klokman; Mars B Van't Veer; Harry Bartelink; Flora E van Leeuwen Journal: J Clin Oncol Date: 2003-07-28 Impact factor: 44.544
Authors: Juan C Lopez-Mattei; Eric H Yang; Maros Ferencik; Lauren A Baldassarre; Susan Dent; Matthew J Budoff Journal: JACC CardioOncol Date: 2021-12-21
Authors: Michael D Chuong; Christopher L Hallemeier; Heng Li; Xiaorong Ronald Zhu; Xiaodong Zhang; Erik J Tryggestad; Jen Yu; Ming Yang; J Isabelle Choi; Minglei Kang; Wei Liu; Antje Knopf; Arturs Meijers; Jason K Molitoris; Smith Apisarnthanarax; Huan Giap; Bradford S Hoppe; Percy Lee; Joe Y Chang; Charles B Simone; Steven H Lin Journal: Front Oncol Date: 2021-10-19 Impact factor: 6.244
Authors: Xin Wang; Nicolas L Palaskas; Brian P Hobbs; Jun-Ichi Abe; Kevin T Nead; Syed Wamique Yusuf; Joerg Hermann; Anita Deswal; Steven H Lin Journal: Cancers (Basel) Date: 2022-03-03 Impact factor: 6.639